BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/12/2026 11:20:20 AM | Browse: 2 | Download: 21
 |
Received |
|
2025-10-20 09:46 |
|
Peer-Review Started |
|
2025-10-20 09:46 |
|
First Decision by Editorial Office Director |
|
2025-10-30 09:37 |
|
Return for Revision |
|
2025-10-31 18:03 |
|
Revised |
|
2025-11-05 15:22 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-12-24 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-24 04:08 |
|
Articles in Press |
|
2025-12-24 04:08 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-29 01:02 |
|
Publish the Manuscript Online |
|
2026-02-12 11:20 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Levodopa: A novel therapeutic prospect for liver disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jun Xu, Ying Qian, Jun-Min Wang, Xing-Li Wu and Yi-Yuan Zheng |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Shanghai Municipal Health Commission |
20234Y0142 |
|
| Corresponding Author |
Yi-Yuan Zheng, Laboratory Center, Department of Gastroenterology, Shanghai Municipal Hospital of Traditional Chinese Medicine, No. 274 Zhijiang Middle Road, Shanghai 200071, China. iceroser@126.com |
| Key Words |
Levodopa; Liver diseases; Liver fibrosis; Dopamine receptor D1; Hippo/YAP pathway; Metabolic dysfunction-associated liver disease; Eating behaviors |
| Core Tip |
This article discusses the potential of levodopa as a novel therapeutic prospect for liver diseases, particularly liver fibrosis and metabolic liver disease. Levodopa, which is traditionally used in the treatment of Parkinson’s disease, may influence liver fibrosis through the modulation of dopamine receptor D1 signaling and the activation of Hippo/YAP pathway. In addition, its potential impact on eating behavior and metabolic regulation may propose it a broader application for patients with stress-exacerbated liver disease. |
| Publish Date |
2026-02-12 11:20 |
| Citation |
Xu J, Qian Y, Wang JM, Wu XL, Zheng YY. Levodopa: A novel therapeutic prospect for liver disease. World J Hepatol 2026; 18(2): 115563 |
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i2/115563.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v18.i2.115563 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
